相关判决书显示，为将肺癌“神药”泰瑞沙纳入医保报销范畴，阿斯利康医药代表自行修改基因检测报告，或与基因检测公司勾结修改报告，甚至未做检测即出报告。视觉中国|图在基因检测申请单上画个不易察觉的“星星”标记，就可以让一些肺癌患者吃上“救命药”，并获得医保 ...

智通财经APP讯，翰森制药 (03692)公布，该集团以下四款创新药续约纳入中国国家医疗保障局、人力资源社会保障部发布的《国家基本医疗保险、工伤保险和生育保险药品目录 (2024 年)》，2024国家医保目录将于2025年1月1日正式执行。

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

2024年9月9日，国际肺癌大会 (WCLC)在美国圣地亚哥举行，在主席研讨会上，一项被称为FURTHER的国际多中心随机研究的中期分析数据公布，该结果为EGFR PACC突变的非小细胞肺癌 ...

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

Approved indications include 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced ...

Clinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...